Patents by Inventor Raja Muthiah

Raja Muthiah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibacterial and antifungal compounds
    Patent number: 11707442
    Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 25, 2023
    Assignees: The General Hospital Corporation, Rhode Island Hospital, A Lifespan-Partner
    Inventors: Helen Burgwyn Fuchs, Eleftherios Mylonakis, Frederick M. Ausubel, Raj Mohan Raja Muthiah, Wooseong Kim
  • ANTIBACTERIAL AND ANTIFUNGAL COMPOUNDS
    Publication number: 20190054048
    Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as Sa bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.
    Type: Application
    Filed: September 23, 2016
    Publication date: February 21, 2019
    Applicants: The General Hospital Corporation, Rhode Island Hospital, A Lifespan-Partner
    Inventors: Helen Burgwyn FUCHS, Eleftherios MYLONAKIS, Frederick M. AUSUBEL, Raj Mohan Raja MUTHIAH, Wooseong KIM
  • Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
    Publication number: 20070004805
    Abstract: A process for preparing a stable aqueous dosage form of sodium 4-phenylbutyrate, including such dosage forms in a highly concentrated solution, as well as methods for making 4-phenylbutyrate and 4-phenylbutyric acid, and for using 4-phenylbutyrate. The stable aqueous dosage forms do not freeze at 0° C.
    Type: Application
    Filed: July 1, 2005
    Publication date: January 4, 2007
    Inventors: Christopher Jobdevairakkam, Raja Muthiah
  • Process of making optically pure L-pipecolic acid and process of making anesthetics and intermediates therefrom
    Publication number: 20060276654
    Abstract: The present invention describes a novel process of preparation of optically pure L-Pipecolic acid and an improved process for the conversion of L-pipecolic acid to L-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide, its hydrochloride salt and hydrochloride monohydrate.
    Type: Application
    Filed: February 9, 2006
    Publication date: December 7, 2006
    Inventors: Jagadeesh Rangisetty, Manik Pullagurla, Raja Muthiah, Christopher Jobdevairakkam